Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Anavex Life Sciences Corp...

    NASDAQ: AVXL · Real-Time Price · USD
    8.27
    -0.29 (-3.39%)
    At close: May 09, 2025, 3:59 PM
    8.25
    -0.24%
    After-hours: May 09, 2025, 05:58 PM EDT
    -3.39%
    Bid 8.25
    Market Cap 706.02M
    Revenue (ttm) n/a
    Net Income (ttm) -46.49M
    EPS (ttm) -0.55
    PE Ratio (ttm) -15.04
    Forward PE 6.39
    Analyst Buy
    Ask 8.69
    Volume 692,258
    Avg. Volume (20D) 1,023,265
    Open 8.50
    Previous Close 8.56
    Day's Range 8.23 - 8.67
    52-Week Range 3.51 - 14.44
    Beta 0.82

    About AVXL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AVXL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AVXL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 months ago
    +8.21%
    Anavex Life Sciences shares are trading higher aft... Unlock content with Pro Subscription
    4 months ago
    +29.55%
    Anavex Life Sciences shares are trading higher after the company announced better-than-expected Q4 financial results.
    news image

    2 months ago · seekingalpha.com

    Anavex: Looking At Different Statistical Approaches Before EMA Opinion

    Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine s...

    news image

    2 months ago · seekingalpha.com

    Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

    Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for the treatment of patients with Alzheimer's Disease by year-end of 2025. The global market for Alzheim...

    news image

    2 months ago · seekingalpha.com

    Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

    Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President & CEO Sandra Boenisch...

    Add to Watchlist